Novo Builds Wegovy’s Cardio Case with Much-Anticipated Data Drop
Novo Nordisk posted new data at AHA 2023 showing that its blockbuster weight loss drug could cut the risk of major cardiovascular events—including heart attack—across patient subgroups.
Novo Builds Wegovy’s Cardio Case with Much-Anticipated Data Drop Read More »
